Literature DB >> 1107066

Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study.

E Pogliani, A D Volpe, R Ferrari, P Recalcati, C Praga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1107066

Source DB:  PubMed          Journal:  Farmaco Prat        ISSN： 0430-0912


× No keyword cloud information.
  6 in total

1.  Potentiation by adrenaline of human platelet activation and the inhibition by the alpha-adrenergic antagonist nicergoline of platelet adhesion, secretion and aggregation.

Authors:  F Lanza; J P Cazenave; A Beretz; A Sutter-Bay; J G Kretz; R Kieny
Journal:  Agents Actions       Date:  1986-08

2.  Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.

Authors:  B Saletu; E Paulus; L Linzmayer; P Anderer; H V Semlitsch; J Grünberger; L Wicke; A Neuhold; I Podreka
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

3.  Prostaglandin and thromboxane biosynthesis inhibitors.

Authors:  R J Gryglewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

Review 4.  Therapeutic use of nicergoline.

Authors:  Bengt Winblad; Mario Fioravanti; Tomas Dolezal; Inara Logina; Ivan Gospodinov Milanov; Dinu Cristian Popescu; Alina Solomon
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

Review 5.  A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Authors:  Mario Fioravanti; Taku Nakashima; Jun Xu; Amit Garg
Journal:  BMJ Open       Date:  2014-07-30       Impact factor: 2.692

Review 6.  Safety of nicergoline as an agent for management of cognitive function disorders.

Authors:  Bernd Saletu; Amit Garg; Ahsan Shoeb
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.